Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High ...

Types Of Non-Hodgkin's Lymphoma

SOURCES:

American Cancer Society: "Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma," "Tests for Non-Hodgkin Lymphoma," "Treating B-Cell Non-Hodgkin Lymphoma," "Types of B-Cell Lymphoma," "Types of T-Cell Lymphoma," "What is Non-Hodgkin Lymphoma?"

Cancer.Net: "Lymphoma - Non-Hodgkin: Subtypes."

Leukaemia Foundation: "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell Lymphoma," "Non-Hodgkin Lymphoma," "Peripheral T-cell Lymphoma."

Lymphoma Research Foundation: "Peripheral T-Cell Lymphoma," "Understanding Non-Hodgkin Lymphoma."

Macmillan Cancer Support: "Primary mediastinal large B-cell lymphoma."

Mayo Clinic: "Non-Hodgkin's lymphoma: Diagnosis & treatment."

Types Of Immunotherapy For Lymphoma

SOURCES:

National Cancer Institute: "Immunotherapy to Treat Cancer," "Biological Therapies for Cancer," "CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers."

American Society of Clinical Oncology: "Understanding Immunotherapy."

American Cancer Society: "What Is Cancer Immunotherapy?" "Immunotherapy for Non-Hodgkin Lymphoma," "Treating B-Cell Non-Hodgkin Lymphoma," "Whole-Body (Systemic) Treatments for Skin Lymphomas," "Immunotherapy for Hodgkin Lymphoma," "Treating Nodular Lymphocytic Predominant Hodgkin Lymphoma (NLPHL)," "Treating T-Cell Non-Hodgkin Lymphomas," "Treating Classic Hodgkin Lymphoma, by Stage," "CAR T-Cell Therapies."

Libre Pathology: "Lymphoma."

American Society of Clinical Oncology: "Lymphoma - Non-Hodgkin: Treatment Options."

Genentech Inc.: "Highlights of Prescribing Information: Rituxan," "Highlights of Prescribing Information: Rituxan Hycela."

National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN Guidelines): "B-Cell Lymphomas, Version 3.2018 -- April 13, 2018," "Primary Cutaneous B-Cell Lymphomas, Version 2.2018 -- January 10, 2018," "Hodgkin Lymphoma, Version 3.2018 -- April 16, 2018," "T-Cell Lymphomas, Version 3.2018 -- February 22,2018."

U.S. National Library of Medicine, MedlinePlus: "Thalidomide."

Chemocare: "Rituxan," "Campath."

City of Hope: "FDA-approved CAR T Cell Therapy for Non-Hodgkin Lymphoma."

Onureg By Bristol-Myers Squibb For Marginal Zone B-cell Lymphoma: Likelihood Of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Onureg overview

Azacitidine (Onureg) is a pyrimidine analogue acts as an anti-anemic and anti-neoplastic agent. It is formulated as tablets and film-coated tablets for oral route of administration. Onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

The drug candidate is under development for the treatment of relapsed and refractory acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelomonocytic leukemia, hairy cell leukemia, marginal zone lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma and lymphoplasmacytic lymphoma, peripheral T-cell lymphomas (PTCL) including angioimmunoblastic T-cell lymphoma (AITL)/immunoblastic lymphadenopathy, follicular T-cell lymphoma, myelodysplastic syndrome, non-small cell lung cancer, metastatic melanoma, solid tumors, non-Hodgkin lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma.

It was under development for the treatment of anal cancer, Merkel cell carcinoma, cervical cancer, nasopharyngeal cancer, pancreatic cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, multiple myeloma, HPV associated nasopharyngeal cancer, liposarcoma, metastatic breast cancer.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

For a complete picture of Onureg's drug-specific PTSR and LoA scores, buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData's Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData's Pharmaceutical Intelligence Center.

---